JP2013511539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511539A5 JP2013511539A5 JP2012540064A JP2012540064A JP2013511539A5 JP 2013511539 A5 JP2013511539 A5 JP 2013511539A5 JP 2012540064 A JP2012540064 A JP 2012540064A JP 2012540064 A JP2012540064 A JP 2012540064A JP 2013511539 A5 JP2013511539 A5 JP 2013511539A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- active agent
- item
- salt
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 152
- 239000000203 mixture Substances 0.000 claims description 87
- 150000003839 salts Chemical class 0.000 claims description 57
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 48
- 239000013543 active substance Substances 0.000 claims description 48
- 125000003277 amino group Chemical group 0.000 claims description 38
- 239000002585 base Substances 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 150000007522 mineralic acids Chemical class 0.000 claims description 20
- 229920002214 alkoxylated polymer Polymers 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 17
- 239000002253 acid Chemical class 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 239000012458 free base Substances 0.000 claims description 14
- 229920003169 water-soluble polymer Polymers 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 229960004768 irinotecan Drugs 0.000 claims description 12
- -1 poly (alkylene glycol Chemical compound 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 10
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 10
- 229940127093 camptothecin Drugs 0.000 claims description 10
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000011541 reaction mixture Substances 0.000 claims description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 8
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000002861 polymer material Substances 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229910000799 K alloy Inorganic materials 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 150000002009 diols Chemical class 0.000 claims description 4
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 150000003384 small molecules Chemical group 0.000 claims description 4
- 125000001302 tertiary amino group Chemical group 0.000 claims description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical group [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims description 3
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical group CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 claims description 2
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 claims description 2
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 claims description 2
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 150000008043 acidic salts Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 150000004703 alkoxides Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000007046 ethoxylation reaction Methods 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- 229920001897 terpolymer Polymers 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 229950011008 tetrachloroethylene Drugs 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26246309P | 2009-11-18 | 2009-11-18 | |
| US61/262,463 | 2009-11-18 | ||
| US29007209P | 2009-12-24 | 2009-12-24 | |
| US61/290,072 | 2009-12-24 | ||
| PCT/US2010/057289 WO2011063156A2 (en) | 2009-11-18 | 2010-11-18 | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015199074A Division JP2016006127A (ja) | 2009-11-18 | 2015-10-07 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511539A JP2013511539A (ja) | 2013-04-04 |
| JP2013511539A5 true JP2013511539A5 (enExample) | 2013-11-21 |
| JP5951496B2 JP5951496B2 (ja) | 2016-07-13 |
Family
ID=43639124
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540064A Active JP5951496B2 (ja) | 2009-11-18 | 2010-11-18 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
| JP2012540065A Active JP5901073B2 (ja) | 2009-11-18 | 2010-11-18 | マルチアームポリマー−薬物コンジュゲートの塩形態 |
| JP2015199074A Pending JP2016006127A (ja) | 2009-11-18 | 2015-10-07 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540065A Active JP5901073B2 (ja) | 2009-11-18 | 2010-11-18 | マルチアームポリマー−薬物コンジュゲートの塩形態 |
| JP2015199074A Pending JP2016006127A (ja) | 2009-11-18 | 2015-10-07 | ポリマー−薬物コンジュゲートの酸性塩形態及びアルコキシル化方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US9226969B2 (enExample) |
| EP (3) | EP3498754A1 (enExample) |
| JP (3) | JP5951496B2 (enExample) |
| KR (2) | KR101790804B1 (enExample) |
| CN (2) | CN102711837B (enExample) |
| AU (1) | AU2010321882B2 (enExample) |
| BR (2) | BR112012011947B8 (enExample) |
| CA (3) | CA2780645C (enExample) |
| CY (1) | CY1121700T1 (enExample) |
| DK (1) | DK2501413T3 (enExample) |
| EA (2) | EA023503B1 (enExample) |
| ES (2) | ES2623677T3 (enExample) |
| HR (1) | HRP20191138T1 (enExample) |
| HU (1) | HUE043689T2 (enExample) |
| IL (2) | IL219866A (enExample) |
| LT (1) | LT2501413T (enExample) |
| ME (1) | ME03396B (enExample) |
| MX (2) | MX337393B (enExample) |
| PL (1) | PL2501413T3 (enExample) |
| PT (1) | PT2501413T (enExample) |
| RS (1) | RS58901B1 (enExample) |
| SI (1) | SI2501413T1 (enExample) |
| SM (1) | SMT201900294T1 (enExample) |
| WO (2) | WO2011063158A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| CA2780645C (en) | 2009-11-18 | 2018-01-16 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| JP6138140B2 (ja) * | 2011-10-25 | 2017-05-31 | ネクター セラピューティクス | 癌患者の治療 |
| WO2013162387A1 (en) * | 2012-04-26 | 2013-10-31 | Amylex Pharmaceuticals, Inc | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof |
| JP6300460B2 (ja) * | 2012-07-20 | 2018-03-28 | キヤノン株式会社 | 化合物、および前記化合物を有する光音響イメージング用造影剤 |
| WO2014036566A1 (en) * | 2012-08-31 | 2014-03-06 | Virginia Commonwealth University | Clickable polyoxetane carrier for drug delivery |
| CN104813167B (zh) | 2012-11-28 | 2019-04-09 | 尼克塔治疗公司 | 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 |
| US9493766B2 (en) * | 2013-02-04 | 2016-11-15 | Corning Incorporated | PCR reaction cleanup buffers |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| WO2014194289A1 (en) | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| CN104225611B (zh) * | 2013-06-18 | 2017-06-30 | 天津键凯科技有限公司 | 达沙替尼与非线性构型聚乙二醇的结合物 |
| CA3191031A1 (en) | 2013-09-27 | 2015-04-02 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| CN106061483B (zh) * | 2013-10-04 | 2021-01-08 | 普洛林克斯有限责任公司 | Sn-38的缓释结合物 |
| JP5721806B2 (ja) * | 2013-10-04 | 2015-05-20 | Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 | 副作用のない抗癌剤 |
| AU2015206667B2 (en) | 2014-01-14 | 2020-05-14 | Nektar Therapeutics | Combination-based treatment method |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3228650B1 (en) * | 2014-12-04 | 2022-03-09 | Delta-Fly Pharma, Inc. | Novel peg derivative |
| EP3253777B9 (en) * | 2015-02-04 | 2021-11-17 | United Arab Emirates University | Rvg derived peptides |
| AU2016305087B2 (en) | 2015-08-12 | 2022-01-20 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| CN107019803B (zh) * | 2016-01-29 | 2020-09-15 | 北京键凯科技股份有限公司 | 具有低成瘾作用的聚乙二醇化阿片样物质 |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| CN107469089B (zh) * | 2016-06-07 | 2022-01-07 | 北京键凯科技股份有限公司 | 一种peg连接子及配基药物偶联物 |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| AU2018207283C1 (en) | 2017-01-10 | 2024-05-02 | Nektar Therapeutics | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods |
| WO2018143122A1 (ja) * | 2017-02-02 | 2018-08-09 | アルプス電気株式会社 | 平衡式電流センサ |
| KR102279429B1 (ko) | 2017-04-21 | 2021-07-20 | 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. | 멀티 암 표적 항암 콘쥬게이트 |
| CN108727584B (zh) * | 2017-04-21 | 2021-01-05 | 博瑞生物医药（苏州）股份有限公司 | 抗癌偶联物 |
| WO2019046452A1 (en) * | 2017-09-01 | 2019-03-07 | Arizona Board Of Regents On Behalf Of Arizona State University | THIXOTROPIC BIOCOMPATIBLE GEL FOR OBSERVATION OF LIVING CELLS IN COMPUTER-ASSISTED TOMOGRAPHY ON CELLS |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| WO2019096096A1 (zh) * | 2017-11-14 | 2019-05-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂靶向偶联物 |
| CN107854693B (zh) * | 2017-11-14 | 2020-07-14 | 高瑞耀业(北京)科技有限公司 | 整合素受体靶向的抗癌偶联物 |
| CN109776787B (zh) * | 2017-11-14 | 2021-08-03 | 博瑞生物医药（苏州）股份有限公司 | 多臂靶向偶联物 |
| CN111526891B (zh) * | 2017-12-27 | 2023-10-20 | 三洋化成工业株式会社 | 药品原料药用原料或药品用添加物和使用了它们的药品原料药或药品 |
| JP2021510702A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 相乗的がん治療 |
| CN112367985A (zh) | 2018-01-31 | 2021-02-12 | 明尼苏达大学董事会 | 用于治疗肺水肿或肺炎的组合物和方法 |
| CN110256533B (zh) * | 2018-03-12 | 2022-05-10 | 博瑞生物医药（苏州）股份有限公司 | 一种高纯度的多臂抗癌偶联物的提取方法 |
| CN110577552A (zh) * | 2018-06-08 | 2019-12-17 | 遵义医学院 | 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用 |
| EP3852793B1 (en) | 2018-09-17 | 2025-11-19 | The Children's Hospital Of Philadelphia | Macromolecular prodrug peg-[sn22]4 |
| CN111603567B (zh) | 2019-02-22 | 2024-12-27 | 赣江新区博瑞创新医药有限公司 | Cd44靶向多臂偶联物 |
| US20220305025A1 (en) * | 2019-08-15 | 2022-09-29 | The Research Foundation For The State University Of New York | Phosphatidylserine binding molecules block immune suppression of tumor associated exosomes |
| MX2022011821A (es) | 2020-03-27 | 2022-10-10 | Univ Minnesota | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. |
| CN114705801B (zh) * | 2022-01-24 | 2024-02-27 | 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) | 一种利福霉素类药物中亚硝酸根离子的测定方法 |
| WO2025053315A1 (ko) * | 2023-09-08 | 2025-03-13 | 파로스젠 주식회사 | 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1222261B (de) * | 1963-04-20 | 1966-08-04 | Bayer Ag | Verfahren zur Herstellung von Polyaethern durch Polymerisation von Alkylenoxyden |
| GB1157753A (en) * | 1966-06-24 | 1969-07-09 | Bp Chem Int Ltd | Improvements in or relating to Synthetic Lubricants |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5399728A (en) * | 1993-04-05 | 1995-03-21 | Arco Chemical Technology, L.P. | Process for the preparation of highly esterified alkoxylated polyol compositions |
| GB9704126D0 (en) * | 1997-02-27 | 1997-04-16 | Ici Plc | Surfactants |
| DE19817676A1 (de) * | 1998-04-21 | 1999-10-28 | Bayer Ag | Verfahren zur aufarbeitungsfreien Herstellung langkettiger Polyetherpolyole |
| AU4564200A (en) | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| DE19937114C2 (de) * | 1999-08-06 | 2003-06-18 | Bayer Ag | Verfahren zur Herstellung von Polyetherpolyolen |
| US6762325B2 (en) * | 2001-05-16 | 2004-07-13 | Nippon Shokubai Co., Ltd. | Method for production of alkoxylated compound |
| SE523934C2 (sv) * | 2001-09-24 | 2004-06-01 | Perstorp Specialty Chem Ab | Förfarande för av alkoxylering av di-, tri och polyalkoholer |
| US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
| BR0315198A (pt) * | 2002-10-09 | 2005-08-30 | Insert Therapeutics Inc | Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos |
| US20050043215A1 (en) * | 2003-02-19 | 2005-02-24 | Tamara Minko | Complex drug delivery composition and method for treating cancer |
| PT2644206T (pt) * | 2003-05-23 | 2019-07-10 | Nektar Therapeutics | Derivados de peg contendo duas cadeias de peg |
| CN1852740B (zh) * | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
| US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| EP1725262B1 (en) * | 2004-03-15 | 2021-05-26 | Nektar Therapeutics | Polymer-based compositions and conjugates of hiv entry inhibitors |
| US7897772B2 (en) * | 2004-10-01 | 2011-03-01 | Kabushiki Kaisha Yakult Honsha | Acid addition salt of irinotecan |
| US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
| EP1926768B1 (en) * | 2005-07-18 | 2011-09-14 | Nektar Therapeutics | Branched functionalized polymers using branched polyol cores |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| IE20060565A1 (en) * | 2006-07-28 | 2008-02-06 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
| JP5105166B2 (ja) * | 2007-12-19 | 2012-12-19 | 公益財団法人野口研究所 | ポリエーテルの製造方法 |
| CA2780645C (en) | 2009-11-18 | 2018-01-16 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
-
2010
- 2010-11-18 CA CA2780645A patent/CA2780645C/en active Active
- 2010-11-18 EA EA201200751A patent/EA023503B1/ru unknown
- 2010-11-18 CA CA3063465A patent/CA3063465C/en active Active
- 2010-11-18 ES ES10781794.2T patent/ES2623677T3/es active Active
- 2010-11-18 PT PT10782159T patent/PT2501413T/pt unknown
- 2010-11-18 EP EP19152138.4A patent/EP3498754A1/en active Pending
- 2010-11-18 CN CN201080061613.6A patent/CN102711837B/zh active Active
- 2010-11-18 HU HUE10782159A patent/HUE043689T2/hu unknown
- 2010-11-18 DK DK10782159.7T patent/DK2501413T3/da active
- 2010-11-18 RS RS20190781A patent/RS58901B1/sr unknown
- 2010-11-18 MX MX2012005795A patent/MX337393B/es active IP Right Grant
- 2010-11-18 ES ES10782159T patent/ES2723026T3/es active Active
- 2010-11-18 PL PL10782159T patent/PL2501413T3/pl unknown
- 2010-11-18 JP JP2012540064A patent/JP5951496B2/ja active Active
- 2010-11-18 WO PCT/US2010/057292 patent/WO2011063158A1/en not_active Ceased
- 2010-11-18 HR HRP20191138TT patent/HRP20191138T1/hr unknown
- 2010-11-18 EP EP10782159.7A patent/EP2501413B1/en active Active
- 2010-11-18 EP EP10781794.2A patent/EP2501412B1/en active Active
- 2010-11-18 BR BR112012011947A patent/BR112012011947B8/pt active IP Right Grant
- 2010-11-18 AU AU2010321882A patent/AU2010321882B2/en active Active
- 2010-11-18 KR KR1020127015272A patent/KR101790804B1/ko active Active
- 2010-11-18 CA CA2780779A patent/CA2780779C/en active Active
- 2010-11-18 EA EA201290342A patent/EA024533B1/ru unknown
- 2010-11-18 SM SM20190294T patent/SMT201900294T1/it unknown
- 2010-11-18 SI SI201031891T patent/SI2501413T1/sl unknown
- 2010-11-18 LT LTEP10782159.7T patent/LT2501413T/lt unknown
- 2010-11-18 ME MEP-2019-185A patent/ME03396B/me unknown
- 2010-11-18 BR BR112012011943-5A patent/BR112012011943A2/pt not_active Application Discontinuation
- 2010-11-18 WO PCT/US2010/057289 patent/WO2011063156A2/en not_active Ceased
- 2010-11-18 KR KR1020127015273A patent/KR101779229B1/ko active Active
- 2010-11-18 CN CN201080061609.XA patent/CN102711836B/zh active Active
- 2010-11-18 MX MX2012005794A patent/MX338134B/es active IP Right Grant
- 2010-11-18 US US13/510,587 patent/US9226969B2/en active Active
- 2010-11-18 JP JP2012540065A patent/JP5901073B2/ja active Active
- 2010-11-18 US US13/510,555 patent/US20130143909A1/en not_active Abandoned
-
2012
- 2012-05-17 IL IL219866A patent/IL219866A/en active IP Right Grant
- 2012-05-17 IL IL219865A patent/IL219865A/en active IP Right Grant
-
2014
- 2014-05-21 US US14/284,067 patent/US9320808B2/en active Active
-
2015
- 2015-10-07 JP JP2015199074A patent/JP2016006127A/ja active Pending
-
2016
- 2016-03-21 US US15/075,750 patent/US20160200867A1/en not_active Abandoned
-
2019
- 2019-06-18 CY CY20191100623T patent/CY1121700T1/el unknown
-
2020
- 2020-10-02 US US17/062,457 patent/US11834553B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101790804B1 (ko) | 중합체-약물 콘쥬게이트의 산성 염 형태 및 알콕실화 방법 | |
| US11208530B2 (en) | Multi-arm polyethylene glycol, preparation method and uses thereof | |
| AU2009282413B2 (en) | Multi-arm polymeric alkanoate conjugates | |
| JP2013511540A5 (enExample) | ||
| ES2659778T3 (es) | Conjugado farmacéutico de polietilenglicol-oligopéptido de aminoácidos-irinotecán y composición farmacéutica del mismo | |
| CN112778403A (zh) | 环肽类抗肿瘤活性化合物及其制备方法与应用 | |
| CN101306203A (zh) | 亲水性聚合物-黄杨木提取物的结合物及其药物组合物 | |
| AU2010321880B2 (en) | Acid salt forms of polymer-drug conjugates and alkoxylation methods | |
| HK1170934B (en) | Acid salt forms of polymer-drug conjugates | |
| HK1137647A1 (en) | Method for preparing a polymer conjugate | |
| HK1137647B (en) | Method for preparing a polymer conjugate |